Abstract
AIM: Numerous quality improvement initiatives for rectal cancer surgery have focused on textbook outcome parameters. In these studies, resection rate and patients who did not undergo surgery are not included, but these parameters might help to evaluate the surgical care for rectal cancer. The aim of this study is to assess the variation of non-metastatic rectal cancer resection rates among hospitals and its effect on patient outcomes.
METHODS: All patients diagnosed with non-metastatic rectal cancer between 2013 and 2018 were selected from the Netherlands Cancer Registry. Hospitals were categorized in quartiles according to resection rates. A multivariable logistic analysis was performed to determine variation in resection rate between these quartiles using a logistic regression analysis to correct for confounders. The association between resection rates and survival was analyzed using Kaplan-Meier method and Cox-regression analysis.
RESULTS: A total of 22,530 patients were included in the analysis. Resection rates varied from 68 to 89% between hospitals. After multivariable analysis, resection rate remained significantly different among the quartiles when correcting for several factors (odds ratio (95%Confidence-interval) 1.71 (1.56-1.88), 2.42 (2.19-2.67), and 4.04 (3.61-4.53) for increasing resection rate quartiles, in reference to the lowest quartile). A higher resection rate was associated with better overall survival, in multivariable analysis this survival benefit could no longer be identified.
CONCLUSION: There is a substantial variation in resection rates for rectal cancer among hospitals in the Netherlands with an impact on overall survival. This may be a relevant issue when analyzing the overall quality of rectal cancer care.
Original language | English |
---|---|
Pages (from-to) | 2384-2389 |
Number of pages | 6 |
Journal | European Journal of Surgical Oncology |
Volume | 47 |
Issue number | 9 |
DOIs | |
Publication status | Published - Sept 2021 |
Bibliographical note
AcknowledgementsThe authors thank the registration team of the Netherlands
Comprehensive Cancer Organisation (IKNL) for the collection of
data for the Netherlands Cancer Registry as well as IKNL staff for
scientific advice.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.